Detalhe da pesquisa
1.
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
Circulation
; 149(13): 993-1003, 2024 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344820
2.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
N Engl J Med
; 387(21): 1923-1934, 2022 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342113
3.
Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Diabetologia
; 67(7): 1328-1342, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38509341
4.
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Cardiovasc Diabetol
; 23(1): 57, 2024 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38331813
5.
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
Ann Intern Med
; 176(4): 515-523, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36940444
6.
Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Eur Heart J
; 44(24): 2216-2230, 2023 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37259575
7.
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
N Engl J Med
; 380(8): 752-762, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415610
8.
Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
Am Heart J
; 254: 203-215, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150454
9.
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
Ann Intern Med
; 174(11): 1528-1541, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570599
10.
Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death.
Circulation
; 142(12): 1148-1158, 2020 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700639
11.
Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.
Rheumatology (Oxford)
; 60(8): 3789-3798, 2021 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369672
12.
Oxytocin, cortisol, and cognitive control during acute and naturalistic stress.
Stress
; 24(4): 370-383, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33632072
13.
Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.
Ann Intern Med
; 172(6): 369-380, 2020 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32066146
14.
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
JAMA
; 326(17): 1703-1712, 2021 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34633405
15.
The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and Prediction.
Circulation
; 149(12): 914-916, 2024 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38498613
16.
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
Circulation
; 139(10): 1289-1299, 2019 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586730
17.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med
; 377(12): 1119-1131, 2017 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28845751
18.
Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus.
Rheumatology (Oxford)
; 59(3): 495-504, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321417
19.
Targeting Inflammation to Reduce Residual Cardiovascular Risk.
Curr Atheroscler Rep
; 22(11): 66, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32880743
20.
Novel Antiatherosclerotic Therapies.
Arterioscler Thromb Vasc Biol
; 39(4): 538-545, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30816799